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PART I • 
En~mi1ogica1 stuQy 
The following chemical substances were prepared: 
1 • Hexose diphosphate (2) 
2. Hexose monophosphate (2) 
3. Phosphog~ceric acid (2) 
4. Coenzyme I (9) 
5. Hexokinase (6) 
6. Cytochrome reductase (4) 
Under the direction of Dr. O. Boyd Houchins these preparations 
were to have been used for the following: 
1. To stuQy the isolated cytochrome reductase en~e s,rstem and 
the effect of ~- tocopherol phosphate on that system 
according to the method of Haas, Horecker and Hogness (5). 
2. To stuQy the cytochrome reductase enzyme s,ystem in ~-to­
. cophero1 deficiency according to the method of Potter and 
Dubois (2). 
Due to a sudden illness of Dr. O. B. Houchins the above was 
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For the sake of clarity, it is to be understood that the following 
abbreviations will be used throughout this thesis: 
Hb reduced hemoglobin 




NOHb nitric hemoglobin 
PAP p-a.minophenol 
A. Preparation, Properties of and Methods of Determining MHb. 
The prosthetic group of the Hb compounds is an iron protoporphyrin 
termed heme. The reduced, or ferroheme, compound may be reversibly 
oxidized at the iron atom to ferriheme (hematin). The latter combines 
with acids to form ferriheme salts or with alkali to form ferriheme hy-
droxide. (199). Ferroheme may combine with certain nitrogenous substances 
(proteins, pyridine, cyanides) to form. ferrohemochromogens while ferriheme 
forms a corresponding series of ferrihemochromogens. The combination of 
ferriheme and native globin has been performed in vitro and results in 
ferrihemoglobin,MHb. (110). Heubner recommends the term "Hemiglobin" as 
better than JlHb. (100). Ferroheme and native globin forms ferrohemoglobin, 
Hb. The oxidation of Hb which results in MHb is to be contrasted with the 
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oxygenation of Hb which results in the formation of the addition complex, 
oxyferrohemoglobin,Hb02• 
lIb combines reversibly with oxygen, carbon monoxide and nitrous oxide. 
Through the action of strong acids or bases upon lIb the corresponding 
ferrihemes are formed. Oxidation with hydrogen peroxide in the presence of 
large amounts of cyanide or coupled oxidation with ascorbic acid results in 
the formation of pseudo-lIb. (15). Strong oxidation with a variety of agents 
changes the valence of the iron in lIb to form MHb which forms a reversible 
redox equilibrium with Hb. (73). 
Hb and lIb02 do not react with cyanides, flourides or azides while MHb 
combines reversibly with cyanides (17, 208), sulfides (200), peroxides (201), 
flourides (312, 382), azoimoid (337), and azides (337). Like any other 
ferriheme compound it may exist as the base or as the salt. (146). It does 
not combine with oxygen or carbon monoxide. (68, 94). Nitric oxide combines 
with Hb to form a ver,y stable compound from which free Hb cannot easily be 
recovered. With MHb it forms an easily reversible compound which upon 
standing undergoes reduction to the stable Hb compound. 
Colorimetric studies show that MHb in aqueous solution occurs as two 
forms in equilibrium. The equilibrium is dependent mainly on the hydrogen 
ion concentration, so that MHb may be regarded as an indicator with an 
interval of change between pH 6-10. (146). 
While all investigators agree that MHb has less oxygen than Hb02 and 
more than Hb, there is still a great difference of opinion as to whether 
the formula HbO or HbOH (equivalent to Hb20) is correct. ~ observers 
(94, 146, 264, 268, 293, 310) have argued that MHb contains one-half the 
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oxygen of Hb02 _ This is expressed by the formula HbO. On the other hand 
Kuester's (244) formulation of MHb as a ferri compound has been supported 
by the work of others.(70, 72, 245, 246, 383). In terms of oxygen content 
this means that MID> contains only one-fourth the oxygen of Hb02 and was 
originally expressed by Kuester by the formula HbOH (Hb20). Conant and 
Fieser (70) state that the HbOH formula is in accord with their facts 
showing that 1 ~drogen equivalent of oxidizing agent and 1 ~drogen equi-
valent of reducing agent are used up in converting Hb + MHb and reversing 
the procedure, respectively. 
The osmotic measurements of Adair (2) and the ~entrifuge methods of 
Svedberg (359) have shown that the Hb molecule contains 4 atoms of iron 
and has a molecular weight of 66,800. In MHb the iron is in the ferric 
state. 
Neutral MHb has 4 absorption bands at wave length 631, 576, 540, 500. 
Alkaline MHb has 3 bands at wave lengths 600, 576, 540. (291). The deep 
seated difference in the spectrum relation of MHb in neutral and alkaline 
solutions is attributed to the very slight reversal to Hb02- Denes (84) 
reported neutral MHb solution has a maximum absorption in the red portion 
of the spectrum_ Ducou (94) reported that bands at wave length 633 in acid 
medium, 601 in alkaline solution and 607 in sodium flouride solution. 
Crystalline MHb has been prepared by two methods. One depends on the 
oxidation of Hb by potassium ferricyanide and has been used by Hufner and 
otto (177) and Jaderholm (185). The other depends on the autoxidation of 
Hb02 in the presence of alcohol and has been used by Ze,ynek (420). Hufner 
and otto (177) and Haurowitz (146) have prepared it by both methods. The 
starting material in either case was crystalline Hb02 prepared by the 
-5-
method of Terry and Green (365). MHb has been prepared by Hill and Holden 
(153) using ferric tartrate instead of potassium ferricyanide and also by 
Keilin and Hartree (201). 
Crystals prepared by the above methods are microscopic, coffee brown, 
rhombic platelets appearing hexagonal because of incomplete growth at the 
acute angles. They are similar to Hb02 crystals, are completely soluble 
in alkali and precipitated by neutralization. The solubility of the MHb 
on a number of phosphate buffers has been determined and shown to depend 
on the ionic strength of the buffer in the same manner as Hb02. The MHb 
solutions remain stable in a cold room for several weeks. (226). 
Various methods have been reported for the determination of blood 
pigments in the literature and for descriptive purposes may be divided 
into four categories: 
1. Gasometric 
2. Colorimetric 
3. Gasometric and colorimetric 
4. Spectrophotometric 
1. Gasometric 
The carbon monoxide capacity method was first suggested by 
Necloux: and Fontes (265) and elaborated by Van Slyke and co-workers (374, 
375). The method is given in detail by Peters and Van Slyke (286). The 
oxygen capacity method was improved by Conant and Fieser (71). The oxygen 
capacity is determined by the Van Slyke and Neill (377) method before and 
after reduction with sodium anthrahydroquinone beta sulfonate (71) or 
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tetanous tartrate (74). 
The gasometric methods are tedious and require experience and elabo-
. 
rate apparatus. The oxygen capacity method is specific for MHb, but there 
is always the danger of the reoxidation of the laked lib to MHb during the 
aeration with oxygen. This tends to make the final result too low but the 
error is minimized by the use of tartanous tartrate as the reducing agent. 
As it has been pointed out (74), the carbon monoxide methods are disturbed 
by the presence of other pigments. After reduction both hematin and Slib 
may combine with carbon monoxide and thus appear in the results as MRb. 
In both methods MHb is calculated from the difference between two deter-
minations thus magnifying the errors. 
2. Combined Gasometric and Colorimetric Determinations 
Active lib is determined by the carbon monoxide or oxygen combin-
ing power. Total pigment is determined by a variety of methods: color-
imetric cyano-MHb (399, 414), acid hematin (46), MHb (14) or total iron 
(77, 104, 108, 410). The difference between the active lib and total pig-
ment represents MHb. 
These method are not specific. If the oxygen capacity is used 
for the determination of the active lib and the total iron for the Tlib, the 
result will represent all the iron containing pigments, MBb, Slib, hematin 
and some non-lib iron. In the case of the carbon monoxide methods a vari-
able amount of Slib may combine with the gas and be calculated as active 
Sh. The difficulties of the colorimetric methods have been discussed by 
Schwentker (332). They require fresh standards which are difficult to 
prepare and must be constantly rechecked. Turbidity (148), hematin or 
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other colored substances interfere with the cyano-MHb and MHb methods. 
The iron analysis are more accurate but are more difficult to conduct 
and generally require preliminary ashing. 
3. Spectrophotometric Methods 
These methods are based upon the fact that the addition of 
cyanide ion quantitatively converts MHb to cyano-MHb without affecting 
the absorption spectra of either SHb or Hb02• Because the spectrum of 
MHb varies with pH and ionic strength, it is necessary to buffer the 
solution to a known pH and to a reasonably constant salt concentration. 
The buffer is also necessar,y to prevent the cyanide ion from changing the 
clarity of the solution. With these restrictions the method is simple; 
they allow the use of uncleared solutions and may be used in the presence 
of other pigments which are unaffected by cyanide ion. 
Variation of these methods for the determination of blood pigments 
can be found in the following references: (13, 14, 41, 42, 46, 51, 56, 71, 
74, 77, 91, 101, 102, 103, 104, 108, 140, 146, 148, 152, 173, 175, 176, 188, 
196, 203, 235, 244, 265, 275, 286, 301, 304, 332, 349, 361, 374, 375, 376, 
377, 398, 408, 410, 414). 
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B. Methemoglobinemia 
1mb is a fairly well known substanoe now that is has been distinguished 
from SHb (370), and its presenoe in the blood stream can be affected by a 
multitude of different substanoes. Its presenoe in normal circulating blood 
is controversial however. Ammundsen (5) found inaotive or non-oxygen com-
bining Hb (MHb) to an average of 3.5% with a maximum of 14.5% in 82 persons 
who had not taken any MHb produoing drugs. Jung and Issekutz (196) reported 
a maximum of 8% of the THb may be present as MHb in the normal blood. Alt-
meyers' (4) speotrosoopic examinations showed that normal blood contains 1.7% 
MHb. Paul and Kemp (281) tested 100 patients and MHb was found in the plasma 
of all but one. The values ranged from 0.01-0.5 gm.% and the mean MHb was 
0.09 gm.%. Records of 20 blood donors showed values of MHb ranging between 
0.03 and 0.13 gm.%. Clarke et.al.(6l) stated that MHb was not present in 
dogs in detectable amounts and Dognon (91) placed the amount at less than 
1% in dogs and humans. Horecker (172) prepared calf Hb with no other im-
purity other than 0.6% MBb. 
Investigations have shown that MHb is formed during the course of 
putrefaction (216), in the boqy after death (216, 327) and in sterile blood 
solutions (272) which are stored under the usual conditions. The formation 
in the boqy, aocording to Schmidt (327), is due to increased permeability of 
the membranes to MHb forming substances. In the sterile blood solutions if 
the Hb is reduced and stored in the absence of air, the formation of 1mb is 
inhibited or wholly prevented (272). 
Talma (362) and Stadie (350) found the abnormal pigment in the corpus-
cles. The former claimed that MHb is not to be found in the serum and the 
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latter, supported by Ottenberg and Fox (277), found the plasma to be free 
of the pigment. Stadie (350), however, stated that MHb may exist in the 
blood in two distinct conditions; in the plasma alone, a true methemo-
globinemia but rare, or in the red blood cells a condition of polycythemia. 
The latter is the usual occurrence. 
Smith and Wikoff (336) suggested that formation of MHb might destrqy 
the erythrocytes. Adams et. al. (3) showed, however, that there was no in-
creased fragility of the erythrocytes in dogs even after administration of 
MHb producing drugs for three months. 
The formation of MHb after poisoning was shown by Kronig (213) to be 
accompanied by certain morphological conditions of the erythrocytes. Hence 
by staining it was hoped to identify the MHb. The metny1ene blue-eosin 
and acid hemotoxylin-eosin stain showed masses of Hb and masses differing 
from Hb which were taken up by the 1eucocytes after which the' conversion 
to MHb took place. 
MHb also has a noted clinical importance with cases of methemoglobin-
emia being reported as early as 1886 and 1890 (219). The presence of many 
MHb producing substances in commonly used preparations leads to frequent 
cases of methemoglobinemia. Many cases have been recorded in the litera-
ture. Acetanilid usually ingested in fairly large quantities for analgesia 
is the most frequent cau~e of methemoglo~inemia (28, 44, 76, 86, 107, 157, 
189, 236, 248, 257a, 260, 282, 305, 314, 321, 336, 339, 352, 354, 384, 411). 
The physiological action of acetanilid is said to reduce temperature by 
converting Hb02 ~ MHb and interfering with oxidation (305). 
Eight cases of methemoglobinemia have been shown to be due to the 
wearing of nevrly dyed shoes, the dye containing nitrobenzene (355). Similar 
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cases were reported with aniline qyes (405). Malden (237) and others (6, 
368) showed that both aniline and nitrobenzene workers shovred symptoms of 
methemoglobinemia from time to time. Loeb et. ale (231) indicate a long 
line of nitrobenzol poisonings producing methemoglobinemia. Harrington 
(141) shovred that poisoning by aniline and its derivatives may occur through 
the unbroken skin, by direct contact or from saturated clothing, by the in-
halation of vapors or the swallowing of particles with food or saliva. 
Clark and Paul (57) reported the case of a student who spilled a hot 
solution of metanitroaniline and metadinitrobenzene on arms and legs at 
noon. By 11:00 P.M. methemoglobinemia developed to a point of a 60% con-
version of the TEb. 
Many other cases of methemoglobinemia are recorded in literature due 
to such varied causes as the sulfonamides (45, 258), antikamnia and phene-
catine (354), orangiene powders (254) and lobar pneumonia(284). While re-
covery in 24-48 hours is the general rule (135), some deaths have been re-
corded. (76, 254, 314, 321). 
The symptoms of methemoglobinemia are numerous; the most connnon, how-
ever, is cyanosis. This cyanosis has been attributed to MHb (4, 390,402), 
SEb, an unusual degree of unsaturation of venous blood (258), presence of 
aniline black (54, 238, 417) and the colored derivatives of the qyes in-
gested (11, 206). Clinically Garvin (113) reported cyanosis in 90% of the 
cases treated with sulfanilamide at the Cleveland City Hospital. Maximum 
MHb produced was 6.3 gm.% against a THb of 17.0 gm.%. Snodgrass and Ander-
son (345) reported cyanosis in 29.6% and Colebrook and Purdie (65) 50% in 
cases treated similarly. Snapper (344) reported severe cyanosis in pat-
ients with diseased livers who ingested phenacetin. 
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An early work on acetanilid indicates that MHb plays a role in the 
formation of cyanosis. Evidence has accumulated to show that MHb could be 
demonstrated in the blood several hours after ingestion of acetanilid and 
has been demonstrated spectroscopically (44, 85, 92) and by the oxygen 
carrying capacity method (236). At this stage phenols which can be detected 
in the blood stream are at their highest levels and cyanosis is deepest, 
while at a later stage it may be impossible to demonstrate the spectrum of 
MHb though cyanosis is still observed (282). The persistent cyanosis ob-
,served when these MHb producing drugs are ingested for long periods or in 
large doses have been described variously as livid blue, tending to chocolate 
or reddish brown (143, 283), grey or slaty in color, and gives the boqy an 
appearance similar to that seen under ultra-violet light. Following inges-
tion the livid cyanosis developes and at this stage MHb is undoubte~ a 
factor, while as the drug is eliminated the livid blue gives way to a muddy 
grey which persists long after the MHb has disappeared. Small amounts of 
PAP in the tissues have been repeatedly noticed and some observers account 
to it for this condition. (248, 417). Kobert (209) reported that if acetani-
lid is not ingested but introduced parentally, it may not be possible to 
detect the presence of MHb even tho~h cyanosis is seen. 
At this point it should be noted that the spectroscopic method of MHb 
detection is sometimes ineffective at lower levels of MHb concentration. 
Altmeyer (4) showed that non-cyanosed patients receiving suffanilamide had 
had 3% MHb; cyanosed at least 6.3%. Since the spectroscopic method is in-
effective at these levels, it would appear that although evidence POints to 
the cyanosis being due partly to metabolized products of the ingested drugs, 
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MHb probably plays a greater role than the foregoing observations would 
ordinarily indicate. 
Stadie's (348) observations on cyanosis in cases of lobar pneumonia 
indicated that MHb played a very small role in its production. A definite 
relation between the degree of cyanosis and the per cent of arterial un-
saturation was shown. When the former increases the latter increases, and 
the venous unsaturation varies similarly. Since the total oxygen capacity 
was high in all the cases, the author felt that the 1mb played a minor role 
in the causation of cyanosis. 
The following s.ymptomatology has been described as characteristic of 
methemoglobinemia (61):: Cyanosis and appearance of MHb in the blood, head-
ache, dizziness, mental confusion, muscular weakness, and in more severe 
poisonings ataxia, impairment of consciousness and coma. The pulse is 
usually thready and weak, blood pressure usually decreased. Other s.ymptoms 
have been described. (25). 
Meulengracht and Lundsteen (248) and others (10, 92, 342, 417) claimed 
the development of an anemia which disappeared slowly when the drugs were 
discontinued. Malden (237) showed that aniline and nitrobenzene workers 
had normal or high red blood cell count with a decrease in Hb of 5-50% 
based on specific gravity tests. Production of anemia, however, is con-
tested by Morgan and Anderson (257a). 
Various affects on the urine have also been described. Nadler (260) 
claimed the presence of acetanilid though this is extremely doubtful. Prob-
ably acetanilid was detected in the body by the indophenol test on the urine. 
This is further borne out by the experiments of Smith (339) in which no 
acetanilid was found in the feces or urine indicating complete absorption. 
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The urine has been described to be normal in color, black (231), dark red-
dish brown (352), dark reddish amber (157) in various cases of methemoglob-
inemia. P~e (282) described conjugated PAP as forming a wine colored 
urine which turned dark brown or black upon standing. Young (417) noted 
changes in the urine after aniline ingestion from dark brown to dark red 
and then almost black. 
The blood is usually brown or chocolate and turbid both in vivo and 
in vitro (38, 97, 107, 130, 141, 282, 417), does not become red upon shaking 




c. Methemoglobin Formation 
MHb may be produced by a considerable number of drugs and toxic agents. 
(286, 400)0 The various MHb forming agents differ in the amounts of MHb 
they produce, as well as the speed with which the,y form the abnormal pig-
mente Formation also varies with the species. 
Presented here is a Table based on a review of the literature of those 
co.pounds which have been tested for their ability for form MHb. 
A. Benzamine Group 
1. Acetanilid- (10, 22, 60,61, 80, 94, 100, 123, 137, 143, 
154, 155, 157, 214, 218, 220, 221, 232, 280, 
282, 309, 338, 339, 340, 342, 350, 367, 372, 
37~*,-154*, 218*, 234*, 280*, 342*, 419*.) 
20 p-amino- propiophenone - (315, 363) 
3. p-aminobenzophenone - (372) 
4. p-aminoacetophenone - (372) 
5. Aniline- (58, 61, 80, 82, 123, 141, 143, 150, 152, 192, 
223, 237, 262, 309, 311, 324, 331, 340, 350, 
372, 378, 418,-289*, 418*, 419*.) 
6. 2 - aniloethano1 - (19) 
7. Dimethyl aniline - (80, 174, 309,-159*.) 
8. Alpha or beta - napthylamine - (80) 
9. p-nitroaniline - (80) 
10. Monoethy1 aniline - (309) 
11. Trichloroaniline - (309*) 
12. Phenacetin - (39, 98, 123, 159, 184, 350,-159*.) 
13. Acetophenetidine - (159, 220, 221, 309, 373) 
14. Amidopyrine - (39, 99, 209) 
- 15 -
15. l{ydroxylamines - (14,45,80,130,166, 183, 193, 223, 229, 
287, 309, 313, 325, 350.) 
16. l{ydroxy1amine hydrochloride - (309) 
17. Phenylhydrazine hydrochloride - ( 262) 
18. Aminopheno1s - para - (23, 40, 45, 79, 150, 156, 159, 164, 
183, 184, 223, 287, 324, 350, 372, 
373,-340*.) 
ortho- (79, 80, 131, 132, 159, 287.) 
meta - (159) 





Quinones - (9, 23, 105, 1461 159, 161, 164, 167, 180, 229, 
245, 273, 350,-tlO*.) 
l{ydrazobenzene - (164) 
l{ydroxyacetamide - (1) 
Toluidines - (309, 350) 
24. 4:4 - Diaminopheny1 sulfone - (309) 
25. 4:4 - Diacetaminodipheny1 sulfone - (309) 
26. Phenazine - (229) 
27. p - pheny1amine - (309*) 
28. iso - ~lamine - (309*) 
B. Aromatic Nitro Compounds 
1. Nitrobenzene - (123, 133, 150, 159, 163, 164, 183, 193, 
195, 237, 262, 280, 287, 298, 309, 331, 
372, 378.) 
a. Nitrobenzo1 - (130,-80*) 
. b. Meta-ni tro-aniline - (57) 
c. Meta-dinitro-benzene - (57~ 169) 
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2. Nitrog~cerine - (130, 195, 276) 
a. G~co1 dinitrate - (195) 
b. Glycol mononitrate - (195) 
3. Nitrotoluenes - (195,-80*) 
4. Nitroxy1enes - (195) 
5. Dinitro-pheno1 - (80*) 
C. Su1fonamides 
1. Sulfanilamide - (21, 45, 65, 109, 142, 144, 191, 212, 279, 
-309, 341, 381, 398,-49*.) 
a. Sulfapyridine - (212, 341,-50*.) 
b. Sulfathiazole - (212,-50*) 
c. Sodium sulfanilamide - (80*) 
d. Disulphani1amide hydrochloride - (309*) 
2. Prontosi1 - (64, 309,-48*.) 
3. 2p-aminobenzenesulfonamide o-pyridine - (45) 
4. Sulfanilic acid - (309*) 
5. p-aminobenzoic acid - (309*) 
D. Other Organic Compounds 
1. Methylene blue - (53, 90, 127, 128, 178, 180, 181, 261~ 386, 
391, 394, 395, 399,-35*, 117*, 357*.) 
2. Ether or chloroform - (97, 136, 146,-194*.) 
3. P.yridine - (307) 
4. P.yrogal101 - (159, 180, 350, 358) 
5. Azo-compounds (350) 
a. 3:3 - dinitroazoxybenzene - (156) 
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• 
6. Oxidation product of oleic and 1ino1ic acids - (271) 
turpentine ) 
cod liver oil) - (271) 
linseed oil ) 
7. Adrenochrome - (379) 
8. Formaldehyde - (350) 
9. P1asmochin - (80) 
10. Promin - (80) 
11. Ferric tartrate - (153) 
12. Sodium sulfanilate - (80*, 309*) 
13. Aspirin - (39*, 382*, 416*) 
14. Resorcinol - (159*) 
15. Phloroglucinol - (159*) 
16. Uliron - (309*) 
17. Sinzedine - (309*) 
E. Inorganic Compounds 
1. Ferricyanides - (9, 67, 146, 153, 161! 167, 180, 245, 246, 
250, 303, 350, 378,-~0*.) . 
2. Nitrites - (9, 14, 20, 31, 36, 37, 45, 52, 53, 62, 79, 80, 
82, 90, 118, 123, 125, 130t 131t 132, 135, 
145, 150, 161, 167, 178, 1~1, 1~3, 195, 222, 
228, 239, 241, 247, 257, 262, 288, 297, 300, 
309, 319, 333, 334, 335, 350, 378, 386.) 
a. Nitrates - (80, 195, 350) 
3. Arsine - (114, 146, 229, 409.) 
4. Ozone - (253, 350,-80*) 
5. Peroxides - (201, 335, 350,-146*.) 
6. Iodine - (350) 
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7. Ammonium hydroxide - (22.5) 
a. Ammonium sulfate - (3.50) 
8. Chromates and Dichromates - (242, 262, 294, 296.) 
9. Chlorates - (20, 161, 262, 3.50, 3.58,-14*, 20*, 80*, 130*.) 
10. Sodium chloride - (3.50) 
11. Permanganate - (146, 3.50) 
F. Bacteria 
1. Pneumococcus - (43, 121, 126, 269, 283, 3.50.) 
2. Gaertner bacillus - (27, 3.50) 
3. Nitrobacilli - (384) 
4. Streptococcus viridans - (3.50) 
.5. Cholera vibrio - (3.50) 
6. Peroxide forming bacteria - (270) 
* (All references marked by an * have shown an inability to produce MHb 
under the experimental conditions of the particular observer). 
AIry attempt to discuss fullY the entire experimental data represented 
in the preceding Table would be too extensive for this paper. Therefore, 
onlY the more significant works will be discussed. 
I. Acetanilid 
In the experimentation on MHb production by acetanilid three 
points stand out summarilY describing its action in the body: 
1. MHb is formed onlY after certain minimal doses are exceeded. 
The minimal or threshold dose varies with animals. (220). 
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2. The amount of MHb does not increase in direct proportion 
to increase in dose. (168, 330, 399). 
3. There is an upper limit to the formation of MHb regardless 
of the dosage. (58, 85, 98, 330). Administration of amounts beyond that 
produce no greater concentration of MHb, but only increases the length of 
time the MHb persists. 
Lester (220) arbitrarily placed the threshold dose for man at that 
amount of the drug which would produce an average maximum of 0.4 gm. of 
MHb corresponding to 2.7% MHb at a THb of 15.0 gm. 
Since it has been conclusively proven that acetanilid produces MHb 
in vivo not not in vitro, it might be well to cite here some of the ex-
perimental data obtained in controlled poisonings of laboratory animals. 
A group of rats were given 19 mg./kgm. of acetanilid for 13 weeks 
with no ill effects. With an increase in dosage to 400 mg./kgm., growth 
was retarded, MHb produced and death occurred in 9 out of 26 cases. (342). 
The work of Van Loon, et.al. (373) showed no accumulation of MHb in 
dogs with administration of doses of acetanilid up to 72 mg./kgm. for 18 
d~s. Larger doses, 250 mg./kgm., produced temporary methemoglobinemia 
and a decrease in THb. The lethal dose with intravenous injection, how-
ever, was previously shown to be between 350 and 500 mg./kgm. (60). 
Helms (154) states that doses up to 1000 mg./kgm. are not fatal, and 
that the lethal dose for most laboratory animals is around 1500 mg./kgm. 
Twelve grains daily for 16 weeks had no effect upon human subjects. 
Lester's (221) experiments on human subjects showed that acetanilid 
given in 3 doses of 0.5 gm. each d~ caused only a slight additive rise 
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in MHb within the day but a marked rise when given in 1 gm. doses. There 
was no accumulative formation of MHb when 1, 2 and 3 mg. were given daily 
for 5 weeks. 
II. Aniline 
The work of ,Clark, Van Loon and Morissey (61) would indicate a 
striking similarity of action between acetanilid and aniline. It was shown 
that progressively greater amounts of Hb were converted by increasing dos-
age to 100 mg.!kgm. producing a maximum methemoglobinemia of about 70%. 
These responses are linear to the log of t he dose but does not hold for 
larger doses. 200 mg. produced a maximum methemoglobinemia of 75% which 
was not increased by still larger doses of 400-1000 mgm. whether given 
orally or intravenously. 
In general the larger the dose of aniline, the more rapid the 
increase and the longer the duration of the methemoglobinemia; thus doses 
of 200 mg. or larger maintained the concentration of MHb of 70-75% until 
death of the animal 10-20 hours later. Since the formation of MHb is re-
versib1e, it is indicated that the larger doses prolong the time during 
which MHb is formed and the reversal does not occur within the survival 
time of the animal. 
It had been previously noted that the formation of MHb by aniline 
was a slow process, a reaction with a definite time log. Van Slyke and 
Vo1ltnund (378) showed that no 'MHb was formed by 4 molecules at 380 until 
after 2 hours and none by 2 molecules until after 5 hours in vitro. This 
would indioate that aniline, like acetanilid, does not produce MHb di-
rectly but rather from products formed from it by the liver. Aniline mixed 
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with whole blood without a tissue suspension does not form MHb. (252). 
Maximum MHb production in dogs was found to be 70-75% of the 
THb at a minimum dosage of 200 mg./kgm. and is not increased by greater 
dosage. Somewhat higher concentrations have been produced in vitro. (61) • 
. It is suggested that the limitation on MHb formation is due to an equilib-
rium between the oxidation reduction potentials of the products of aniline 
(p-aminophenol-quinamine system) with the MHb-Hb system. (168). 
III. Aminophenols 
Experiments with the derivatives of 0-, m-, and p-aminophenol 
show that the meta derivative is . barely poisonous and the the ortho de-
rivative is more poisonous than the para. (159, 287). The aminophenols 
can penetrate the red blood cell membrane to produce methemoglobinemia. (23). 
It was determined that the quinimine form of p-aminophenol acted 
immediately to a maximal extent while the PAP took some time to do so. The 
former is believed to be the active MHb producer, and this oxidized form 
reacts with the Hb of the red blood cells while the PAP remains in the re-
duced stage. (23). 
Since each molecule of aminophenols reacts several times with Hb 
molecules, the reaction between the oxidized form of PAP and Hb should re-
sult in the formation of more PAP and MHb. (159). 
Toxicity studies in the laboratory were conducted by Brownlee 
and Gaddum (40) and show the following results on rats! 














A total of 960 blood samples were taken from 476 patients receiv-
ing sulfanilamide and were examined for sulfanilamide and MHb. The bloods 
showed that the higher the content of the former, the greater the concen-
tration of the MHb. The average MHb content was proportional to the sulfa-
nilamide concentration. After a single dose of sulfanilamide the maximum 
MHb occurred several hours after maximum blood sulfapilamide peak. It 
. seems that an active substance is normally produced in the course of sulfa-
nilamide metabolism which causes the production of MHb. (142). 
V. Ferricyanide 
Ferricyanide produces MHb quite readily but is unable to pierce 
the membr~es of the cells, therefore the blood must be laked. (378). 
Speqtrophotametric and gasometric determinations have shown that 1 molecule 
of ferricyanide is required to expel 1 molecule of oxygen from Rb02. (9, 67, 
246, 250, 303, 350, 378). The reaction may, therefore, be expressedt 
VI. Nitrites· 
Action of nitrite on Rb is extremely complicated. It is reported 
to vary with the molecular ratio of nitrite to Rb, pH, presence or absence 
of oxygen and reducing agents and possibly others. Among the products of 
reaction found under varying conditions in vitro are :MHb, NOHb and NO-MHb. 














(14, 20, 350) 
(31, 137, 247, 378) 
(9 ) 
(82) 
A source of error in the above reports was lack of analyses for 
residual nitrite. The in vitro work of Greenberg, Lester and Haggard (125) 
indicated this. Their work can be summarized as follows: 
1. Ratio of nitrite and MHb is 1:2. That is, 1 molecule of 
nitrite reacts with 2 molecules of Hb to produce 2 molecules of MHb. 
2. Temperature, concentration of nitrite and pH are without 
influence upon the ratio of nitrite utilized to MHb formed. 
3. In an acid medium the reaction of nitrite with Hb is complete 
in a short time. 
4. In a neutral or slightly alkaline medium the reaction may 
take many hours for completion, depending on concentration of nitrite. 
5. The amount of MHb formed per molecule of nitrite utilized 
cannot be determined directly in vivo, but it is probably the same as in 
vitro. 
Hanzlik (137) reported that nitrite action on Hb is largely a function 
of pH with increasing efficiency in an acid solution up to pH 5 (with in-
creasing acidity). The r'eaction was reported in a ratio of 1:1. At pH 7.0 
he reported an increase in the amount of molecules of nitrite necessary to, 
convert Hb to MHb and true alkalinity allows minute changes. 
Brooks (31) reported that in the presence of a ~educing agent, nitrite 
formed with Hb the same compound as results from the action of nitric oxide 
on reduced Hb: 1 molecule sodium nitrite completely converted 1 equivalent 
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of reduced Hb to NOHb. In the absence of both oxygen a~d a reducing agent, 
1 molecule sodium nitrite combined with 2 equivalents of reduced Hb to pro-
duce 1 equivalent of MHb and 1 equivalent of NOHb. Meier (247) previouslY 
had also stated that nitrite action on Hb02 was influenced by pH. He re-
ported little change in an alkaline solution even if the nitrite was pre-
sent in great excess. In a neutral or weaklY acid reaction only MHb is 
formed if there is a definite molecular relationship between nitrite and 
blood pigment. Below this concentration relationship, Hb02 is present 
along with the MHb, and above it both MHb and NOHb are present. Presence 
of NOHb as well as MHb in the reaction of Hb and nitrite had already been 
noted. (130, 145). In a molecular relationship where only MHb is produced 
about one-fourth of the oxygen bound to the Hb02 is liberated, with a cor-
responding change in nitrite. The reaction may be expressed -
The NOHb appearing in the presence of an excess of nitrite is due to 
a further breakdown of nitric acid into nitrite and nitric oxide with a 
relative deficiency of oxygen in which the MHb is reduced. In the absence 
of oxygen MHb and NOHb are formed from reduced Hb independently of the re-
action. During the acute intoxication of cats with nitrite pronounced MHb 
formation occurs. Upon standing the blood contains onlY NOHb which is due 
to the fact that the reducing substances of the blood or bacterial oxygen 
becomes operative, reacting in the same way as a chemical reducing agent. 
Marshall and Marshall (239), in experiments performed with crystal-
lized ox Hb02 in buffered solutions of sodium nitrite, reported the action 
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of the nitrite on blood shows three periods: induction, reactionary and 
stationar,r. The action is due to nydrolyzed nitrous acid, the primaF,1 
effect being the formation of MHb which results from the nydrolysis of 
nitrogen peroxide. The formation of NOHb is a consecutive action result-
ing from the action of nitric oxide on reduced Hb. The action is facili-
tated by the presence of reducing agents which increase the nitric oxide 
pressure and cause reduction of the Hb02 or MEh. 
On the amount of MHb formed by nitrite in vivo, Wendel (399) re-
ported that 30 mg./kgm. produced a 60-70% decrease in o~gen capacity in 
60-100 minutes. Similar results were reported by Darling and Roughton (82). 
Hug (181) reported maximal appearance of MHb after injection of sodium 
nitrite in 15 minutes. 
Nagazumi (262) and Jung and Bredow (195) reported sodium nitrite to be 
a more intense MHb former than many other substances. The former reported 
87% MHb produced by sodium nitrite in white rats. The minimal lethal dose 
in rabbits was reported at .0876 gm./kgm. (297,300) with death occurring 
when 80% 1lHb was formed. Rappaport (300) reported 99% of Hb-. MHb conver-
sion with higher doses. 
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D. OXidation Product,s of MHb - Producing Drugs 
The amount of MHb found in the blood at any time is resultant of the 
breakdown of such substances as aniline and acetanilid and the production 
of their ox~dation products in the body by the liver (24). Below is a 
diagram which indicates the direction of the normal breakdown of some of 
the benzamine group of drugs. 
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It is well known that the presence of an amine group on the benzene 
ring greatly increases the ease with which the structure can be oxidized. 
The reactions are logical and sound chemically, but are theoretical ph3'sio-
logically in that they have not been proven to take place in the animal 
organism. The oxidation of acetanilid, aniline and phenacetin to PAP both 
in vivo and vitro is well established as the compound has been isolated from 
the urine (124, 252, 417, 419) and blood serum (417, 419) of patients re-
cei ving these drugs. The oxidation of PAP to quinone is easily carried out 
in vitro but has not yet been demonstrated in vivo. 
Many observers have stated p-aminopheno1 to be the active MHb producer 
in aniline or acetanilid poisoning (22, 83, 123, 138, 223, 251, 289, 302, 
324, 326, 353, 404, 413.). The work of Heubner and associates (159, 166) 
working with the simple aniline molecule most clearly substantiate this 
opinion. Although phenylhydroxylamine occurs as an intermediary in the 
oxidation of ami1ine, it is not considered to be the actual MHb former be-
cause of the ease with which it is irreversibly converted in vivo into 
azoxybenzene. (45). This is contrary to the observers who attributed the 
MHb forming action to hydroxy1amines. (98, 122, 135). 
When aniline was given to cats by subcutaneous injection of an aqueous 
solution, it was demonstrated that eight times the theoretical molar equi-
valent of MHb was formed at which stage an equilibrium was established when 
37% of the total blood pigment was oxidized. This justifies Heubner's 
convictions that pheny1hydroxylamine was not responsible, but that the 
oxidation reduction s,ystem set up by p-aminopheno1 and p-iminoquinone was 
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the effective agent. Iminoquinone would be capable of oxidizing 1 molecule 
of Hb to MHb being itself reduced thereby; it could again be oxidized in 
the blood when it would be available to start again. 
The catalytic conversion, as shown below, would proceed until an equi-
1ibrium was reached. 
NH2 NH NH2 
-H2 
)0 +Hb )0 + MHb 
-, 
OH 6 OH 
To fill the roll in this scheme a drug containing an aromatic amino group 
with a hydroxyl radical in the o-orp-position, or with a potential source, 
is required. (39). 
Wendel (391) in his work on the production of MHb by methylene blue 
expounded a tentative theory on the mechanism of its production. Some re-
ducing substance (inductor) present in the corpuscles is oxidized by methy-
lene blue. The 1euco-methy1ene blue forms a peroxide-like compound With 
Hb02- This complex peroxide effects the oxidation of lactic to pyruvic acid 
and is itself thereby converted to MHb, methylene blue and oxygen somewhat 
as follows:: 
Inductor + 4 ME --+ Oxidized inductor + 4 MEH2 
4 MBH2 + Hb (Fe02)4 ~ (MBH2)4 Hb (Fe02)4 (complex peroxide) 
(MBH2)4 Hb (Fe02)4 + 2 lactate ~ 4 ME + Hb (Fe+++)4 + 
2 pyruvate +. 6 H2O + 20a 
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The features of this scheme are: 
1. An inductor, the oxidation of which by methylene blue 
forms carbon dioxide and the leuco-dye. 
2. Reversible action of the dye. 
2. Non-reversible action of the Hb. 
4. The stoichiometric relation between lactic acid oxidized 
and Hb destroyed. 
5. The sum of the oxygen required by these processes is 
one-half of the total oxygen consumption. 
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E. Regeneration (MHb --t> Hb) and Anti-cyanide ion Effects of MHb 
In almost all experimentation on the production of MHb in vivo there 
has been noted a marked regeneration of MHb ...... Hb. This regeneration has 
caused the disappearance of MHb from the blood stream in times varying 
from 5 hours to 2 days. (21, 57, 82, 118, 131, 169, 181, 228, 231, 295, 
296, 311, 399.). 
The lag in the accumulation of MHb in drawn blood was shown to be 
due to the intrinsic enzyme systems of the erythrocytes which reduce MHb 
to Hb. (387). It was discovered that the reducing agents working in vitro 
are formed primarily from glucose by the erythrocytes. Lactic acid, acti-
vated by an intraerythrocytic enzyme system, accounts for 25-50% of the 
reduction. (396). 
The mean rate of disappearance of MHb following injection of the 
sodium nitrite (0.5 cc of a 6% solution/kgm.) is 11.2% of the THb/hour. 
The standard deviation of the mean is ± 2.0% of the THb/hour. The rate 
of MHb disappearance, expressed as per cent of the THb, is independent of 
the total pigment concentration and the MHb concentration. (80). Clark 
and associates (61) showed the rate of regeneration in dogs poisoned with 
aniline to be 4-7% of the THb/hour. Wendel (399) placed the natural re-
ducing system of red blood cells at about 10% of THb/hour. 
From many observations (4, 35, 61, 79, 82, 90, 127, 144, 150, 151, 
, 
160, 288, 325, 351, 381, 397, 399, 407.), it has been found that intra-
venous injections of methylene blue accelerates reduction of MHb ~ Hb. 
Methylene blue has also been shown to be effective by mouth although its 
action is slower and MHb can be prevented by oral administration of 
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0.5-1.0 gm./day. (399). Two possible sources of leuco-methylene blue in 
the body are: a) reduction of methylene blue in the erythrocytes by enzyme 
s,ystems present there, and b) reduction of methylene blue in other tissues • 
... \..- .. 
The rate of the former is not rapid enough to account for all the MHb re-
duced, thus it appears the methylene blue is red~ced in the tissues and re-
turned as such to the erythrocytes. (399). 
Decreased body temperature caused a decreased rate of reduction of 
MHb. Methylene blue was effective in accelerating reconversion of MHb.-, 
Hb at the lower body temperature. The slowness of the conversion was shown 
to be due to the temperature itself. (80). Reconversion in vitro also de-
pended on temperature as well as the intactness of the red blood cells. 
Reconversion failed to occur when the blood was kept on ice or hemo~zed. 
(132). 
Cox and Wendel (80) listed the following factors as not influencing 
the rate of reversion of MHb ~ Hb: 
1. Blood sugar concentration - At comparable temperature in vivo and 
in vitro rates are the same and the elevation of blood sugar in vitro has 
no effect upon the rate during the period required for conversion of 50% 
of the MHb--t Hb. Increase or decrease in vivo also has no effect between 
concentrations of 40-400 Mgo per cent. However, successful use of dextrose 
solutions to revert MHb has been reported. Kos,yakov (210) reported that 
insulin injection favors and glucose administration restricts MHb formation. 
Clark and Paul (57) and Reimann (302) suggested use of isotonic dextrose 
solutions to hasten MHb reversion. Brooks (36, 37) reported actual reduc-
tion of MHb by glucose injection (isotonic dextrose) and an inhibitory 
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effect on MHb production if given before administration of sodium nitrite. 
Zierz (421), however, reported a negative effect of glucose upon MHb re-
version. 
• 20 Prolonged methe.-nog1obinemia - rate remains the same even after 4 
complete reversions of MHb to Hb in 36 hours. Schlossman (325) after 
initial dose of sodium nitrite reported complete reversion of MHb in 6-8 
hours. With repetition for 8-13 weeks MHb could be found 24 hours after 
the last injection. 
3. Fasting - dogs fasting for 3 weeks show no change in ability to 
convert MHb'--' Hb. 
4. MHb concentration - when greater than 20%. 
5. Total pigment. 
6. Two or 3 degrees of fever. 
Various other substances have shown an ability to reduce MHb ...... lIb. 
Sakurai (319) reported use of organ tissues in defibrinated blood having 
a reducing effect upon MHb. Neill (269) reported that living pneumococci 
or their sterile extracts are capable of reducing MHb after the,y have formed 
it from Hb. lliche1 and Harris (253) reported reduction of MHb by sodium 
hydrosulfi te, anunonium sulfide (292), sodium anthrahydroquinone desulforate, 
tetanous tartrate and stokes f reagent. . 
Gutman et. a1. (127) showed that either diphosphonuc1eotide or trip-
phosphonuc1eotide, or both were necessary for the reduction of MHb by 
lactate or adenosine diphosphate. Their work shows that: 
a. When nicotinamide is present, a known suppressor of pyridine 
nucleotide hydrolysis, adenosine diphosphate or lactate can serve as a 
- 33 -
substrate in the reduction of MHb in hemolYsates as well as intact 
erythrocytes, while glucose is no longer utilized after hemolYsis. 
b. MHb interacts with reduced diphosphonucleotide to yield Hb. 
Both these reactions are greatly accelerated by methylene blue. 
The reduction of MHb by glYceraldehyde, ascorbic acid (120, 380), 
cysteine or by the enzymes in the blood, already mentioned here, has been 
investigated. Keise's work (204) on the reduction of MHb was quite ex-
tensive. 
The reduction of glyceraldehyde is proportional to the concentration 
of both reactants and the pH. The reduction by ascorbic acid proceeds more 
rapidly and reaches an as,ymptote with increasing ascorbic acid concentra-
tion. The velocity increases very much more rapidly with a decrease in 
hydrogen ion concentration beyond pH 8 than at pH 7. The reduction of MHb 
by cysteine also proceeds as,ymptoticallY, reaching a maximum value with in-
creasing concentration of cysteine, and the velocity of the reaction is 
maximal at pH 8. The reduction velocity in the intact red blood cells 
attained a maximum at a 0.5% glucose concentration while fructose was less 
effective below 0.5% concentration. A 0.001 M iodoacetate completely 
inhibited the action of both glucose and fructose. If the cells were hemo-
lYzed the MHb was no longer reduced by either glucose or fructose but onlY 
by hexose mono-or diphosphate. The latter reaction is not inhibited by 
iodoacetate. 
The enzyme s,ystem involved in the reduction of MHb by hexose mono-
phosphate consists of at least two components. Besides the "Zwischen-
ferment", which in conjunction with coenzyme reduces hexose monophosphate, 
a 1mb reductase is also required. The reduction by lactate even of small 
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concentration is more effective than by glucose of similar concentration 
and a higher maximum velocity is obtained. The combined action of glucose 
and lactate exceeds the effect of 1 substrate. The reduction by lactate 
is not increased by reversiblY oxidizable Qyes, but by glucose and still 
more by hexose monophosphate. The catalytic action of dyes in the re-
duction of MHb by hexose monophosphate is due to the acceleration of the 
reaction between MHb and MHb reductase. The catalytic effect of the Qyes 
was in the order: 
naphthaquinone > Nile blue > methylene blue, and attains a 
maximum even in very low concentrations. 
MHb appears in the literature fairlY extensivelY as an antidote for 
cyanide ion poisoning. (52, 53, 96, Ill, 117, 128, 17B, lBO, 257, 315, 
316, 31B, 335, 394, 396, 397, 39B.). 
Chen, Rose and Clowes (52) reported methylene blue as being able to 
oppose 2 minimal lethal doses of cyanide ion while amyl nitrite could 
oppose 4. Hug (178) showed that the formation of MHb by methylene blue, 
sodium nitrite or sodium thiosulfate increased survival time of dogs in-
jected with cyanide ion threefold or more. Sahlin (31B) showed that in-
jection of methylene blUe increased the survival time of white mice in-
jected with cyanide ion from 30 minutes to 6 hours or more. 
Chen, Rose and Clowes (53) tested various drugs for efficiency in 
antidoting cyanide ion poisoning. In order of their increasing effect 
was methylene blue, sodium thiosulfate, sodium tetrathionate, amyl 
nitrite, sodium nitrite, methylene blue and sodium tetrathionate, amyl 
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nitrite and sodium thiosulfate, sodium nitrite and sodium tetrathionate. 
The best combination, however, was sodium nitrite and sodium thiosulfate. 
In their combined action the following reactions probablY take place: 
1. NaN02 + Hb --+ MHb 
20 NaCN ... MHb ---p cyano - MHb 
3. Na2S203 + NaCN + ° ---'P NaSCN + Na2S04 
The use of the two drugs together speeds the real detoxification to 
sulphocyanate. 
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F. Data and Discussion 
A. Objective: 
1. To note the effect of increasing amounts of PAP on blood. 
2. To note the effect of increasing amounts of glucose 
(increments of 100 mgm. per cent) on the production 
r of MHb by PAP in blood. 
B. Proceduret 
In the determination of the MHb and the THb the spectrophoto-
metric method of Evelyn and Ualloy (102) was used. All spectrophotomet-
ric measurements were made on the Coleman Universal Spectrophotometer, 
Model llAo 
The calculations for the determination of MHb and THb on the 
Coleman Spectrophotometer are based upon obtaining two calibration 
factors FM and FT which vary from one spectrophotometer to another. The 
procedure used in obtaining these factors is taken from the text "Prac-
tical Physiological Chemistry" by Hawk, Oser and Summerson, 12th Edition. 
A normal sample of blood was obtained and its Hb content was 
measured by either the iron method of Wong (410) or the gasometric method 
of Van Slyke (374), using the procedure as outlined by Van Slyke and 
Neill (377). 
The FM factor is obtained by dividing the THb, as obtained in 
the method of Wong or Van Slyke, by the difference in the Dl and D2 read-
ings; the FT factor by dividing the THb by the D3 reading as described in 
the method of Evelyn and Malloy (102). The ~ reading is simply of the 
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diluted, buffered blood read at a wave length of 635. The D2 reading is 
the same except for the addition of neutralized sodium cyanide. The D3 
reading is of the diluted blood in a potassium ferricyanide sodium cyanide 
buffered solution read at 540. The limit of precision of both the MHb 
and the THb analYses is about 0.1-0.2 mgm. per 100 cc. 
The factors obtained for our spectrophotometer were FM • 42.3 
and FT = 49.6. MHb and THb determinations are based on the formulae: 
MHb (gm %) = (DJ. - D2) x FM 
THb (gm %).. D3 x FT 
The principle of this determination is that MHb has a character-
istic light absorption at a wave length of 635. This is abolished in the 
presence of cyanide which converts the MHb to cyano-MHb. The difference 
in light absorption at a wave length of 635 before and after adding 
cyanide is a measure of the MHb present. THb is determined by converting 
all the Hb present to cyano-MHb and measuring the light absorption at a 
wave length of 540. 
All cuvettes used were opticallY matched using a methyl red 
solution at a wave length of 480. All reference standards used contained 
the same amounts of PAP and buffer mixture as the diluted blood sample. 
All blood samples were prepared by diluting 1 cc of blood to 
100 cc with phosphate buffer of pH 6.6. Specific amounts of 0.01 M PAP 
were added to individual tests and their MHb producing ability was measured. 
On some samples, glucose in increments of 100 mgm. per cent was added to 
the blood, buffer and PAP solution. All solutions were incubated at 37°C. 
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The majority of samples lost their clarity after about 2 hours 
incubation, due probably to the oxidation products of PAP. In the advent 
of the lack of absolute clarity the solutions were centrifuged and the clear 
solution obtained was used. By comparison of D3 readings in identical cen-
trifuged and clear non-centrifuged samples, it was determined that the cen-




0.25' cc PAP 
(1) (2) 
Time(hrs. ) THb MHb ~ MHb Time (hrs. ) THb MHb ~MHb 
,-
I 11.98 1.32 11.0 1 13.24 2.18 16.5 
3 2.21 17.6 3 2.84 21.4 
7 4.28 35.8 7 5.42 40.8 
23 5.40 45.2 23 9.45 71.3 
(3) (4) 
Tiiiie(nrs. J THb MHb ~ MHb Time{hrs. ) THb MHb ~ MHb 
1 13.62 1.39 10.2 1 6.60 .91 13.8 
3 2.81 20.6 3 1.57 23.8 
7 5.16 37.9 7 3.27 49.5 
23 6.15 45.2 23 4.87 73.7 
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TABLE II. 
0.5 cc PAP 
(5) (6 ) (7) 
Time Time Time 
(brs.) THb MHb % MHb (hrs.) THb MHb % MHb (brs.) THb MHb %MHb 
2 11.32 2.09 19.4 2 8.31 1.99 2h.O 2 8.35 1.92 23.0 
3 3.09 26.6 3 2.58 31.0 3 2.50 30.0 
8 7.36 65.0 8 6.23 75.0 8 5.66 67.7 
12 8.66 76.5 12 6.18 74.5 12 6.55 78.4 
24 5.88 52.0 24 4.28 51.6 24 5.82 69.6 
(8) (9) (10) 
Time Time Time 
(hrs.) THb MHb % MHb (brs.) THb MHb % MHb (brs.) THb MHb % MHb 
2 13.69 2.58 18.8 1 9.29 1.57 16.9 1 7.82 1.52 19.5 
3 3.73 27.2 2 2.34 25.2 2 2.16 27.6 
8 8.13 59.3 4 5.00 53.8 4 4.64 59.3 
12 11.40 83.1 8 7.87 84.6 8 6.45 82.5 
24 7.33 53.6 24 6.62 71.2 24 4.90 62.7 
(11) (12) (13 ) 
Time Time Time 
(brs.) THb MHb %MHb (hrs.) THb MHb % MHb (brs.) THb MHb % MHb 
2 11.90 1.06 8.91 2 11.85 .• 72 6.07 2 18.60 3.00 16.1 
4 1.74 14.6 4 2.07 17.4 4 6.18 33.2 
8 5.46 45.9 8 6.61 55.7 8 9.93 53.4 
16 10.27 82.3 16 11.01 93.0 12 11.38 61.2 
24 10.80 90.6 24 10.40 88.7 24 4.39 23.6 
(14) (15) 
Time Time -
~hrs.) THb MHb % MHb (brs.) THb MHb %MHb 
2 11.41 .92 8.06 2 15.55 061 3.94 
4 2042 21.2 4 3006 19.7 
8 4.42 38.8 8 5.36 34.4 
12 7.83 68.7 12 9.03 58.2 
24 6.06 53.0 24 12027 78.8 
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TABLE III. 
Icc of PAP 
(16) (17) (18) 
Time Time Time 
(hrs.) THb MHb % MHb (brs.) THb MHb %MHb (brs.) THb MHb %MHb 
1 9.87 1.42 14.7 1 11.67 2.34 20.2 1 13.55 2.79 20.6 
2 2.39 24.2 2 4.10 35.1 2 4.12 30.3 
4 4.40 44.5 4 5.80 ·49.7 4 6.62 48.7 
8 8.08 81.8 6 7.22 61.8 6 8.89 65.5 
12 8.77 88.9 8 10.87 93.2 10 11.68 86.2 
24 5.43 55.1 24 7.15 61.2 24 9.75 72.0 
(19) (20) 
Time Time 
(brs o ) THb MHb % MHb (brs.) THb MHb % MHl>_ 
1 14.60 2.69 18.4 1 9.25 1.81 19.6 
2 5.74 39.4 2 3.76 40.7 
4 9.41 64.4 4 60 24 67.4 
6 11073 800 4 6 7.42 80.2 
8 13.34 91.4 8 8.88 96.0 
12 13.60 93.1 12 7.96 86.1 
























· TABLE IV. 
















(hr5.) THb MHb % MHb 
1 17.7 2.77 15.7 
2 8.26 46.6 
4 14.35 81.0 
8 15.90 89.8 
(24) 
Time 
(hr5.) THb MHb % MHb 
1 17.0 3.92 23.2 
2 8.44 49.6 
4 15.78 93.5 
8 16.10 94.7 
TABLE V. 
PAP ~ Increments of Glucose 
Based on 100 mgm. Based on 100 mgm. Based on 200 mgm. 
glucose glucose glucose 
(See Table 9) (25) (Table 10) (26) (See Table 11) (27) 
Time Time Time 
(brs.) THb MHb %MHb (brs.) THb MHb %MHb (brs.) THb MHb % MHb 
1 9.29 1.98 21.3 1 7.82 1.28 16.4 2 11.90 1.59 13.4 
2 2.16 23.2 2 1.97 25.2 4 2.13 17.7 
4 5.35 53.5 4 4.17 53.3 8 5.67 47.6 
8 8.10 87.0 8 5.73 73.3 16 11.30 94.9 
24 6.00 64.5 24 4.53 58.0 24 10.90 91.3 
Based on 200 mgm. Based on 150 mgm. Based on 300 mgm. 
glucose glucose glucose 
(See Table 12) (28) (See Table 13) (29) (See Table :13) (0) 
Time Time Time 
(brs.) THb MHb %MHb (brs.) THb MHb % MHb (hrs.) THb MHb % MHb 
2 11.85 .78 6.58 2 18.60 3.04 16.3 2 18.60 2.93 15.7 
4 1.99 16.8 4 5.61 31.5 4 5.L5 29.2 
8 6.15 51.9 8 9.54 51.3 8 10.67 57.3 
16 9.28 78.3 12 14.18 76.2 12 14.36 77.0 
24 8.60 72.5 24 10.79 58.0 14 10.71 57.6 
Based on 450 mgm. Based on 400 mgm. Based on 400 mgm. 
glucose glucose glucose 
(See Table g) (1) (See Table 1~) (2) (See Table l!) (3) 
Time Time Time 
(brs.) THb MHb %MHb (brs.) THb MHb %MHb (brs.) THb MHb %MHb 
2 18.60 4.35 23.4 2 11.41 1.88 16.5 2 15.55 2.24 14.4 
4 7.50 40.3 4 2.77 24.2 4 3.24 20.8 
8 11072 63.0 8 3.36 29.4 8 3.68 23.6 
12 10.73 57.7 12 3.75 32.8 12 4.06 26.1 
24 4.75 41.6 24 3.48 22.4 
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c. Interpretation 
Table I - Use of 0.25 cc of 0.01 M PAP results in a rapid initial 
production of MHb. After the large initial production, the rate 
of formation seems to taper with the maximum amount not yet at-
tained at the end of 23 hours. The THb seemingly has no effect 
upon either the rate of production or the percentage of MHb pro-
duced within 24 hours. This is shown by comparing Tables 2, 3 
and 4. 
Table 2 has a THb of 13.24, an initial production of 
16.5% and a maximum production of 71.3% at the end of 23 hours. 
Table 3 with a similar THb of 13.62 has an initial rate of 10.2% 
and a total production at the end of 23 hours of only 45.2%. 
Table 4 which has a THb of about one-half the previous has an 
initial rate of 13.8% and a total production within 23 hours of 
73.7%. 
Table II - Use of 0.5 cc of 0.01 M PAP brings the peak of MHb pro-
duction within 24 hour range in most cases. Tables 6, 9 and 10 
show the maximum reached from the 8th to the 24th hour; Tables 
5, 7, 8, 13 and 14 narrow this limit to the 12th -24th hour. 
Table 12 shows the peak at about the 16th hour while in only 2 
cases, Tables 11 and 15, the peak of production had not yet 
been reached at the end of 24 hours. The initial rate varies 
from one sample to another, and again the evidence is that the 




Table III - With the increase of the 0.01 M PAP to 1 cc the time of 
maximum production is again shortened from the 16 hours of Table II 
to about 9-11 hours. The initial speeds are about 20% for samples 
varying in THb from 9.25-14.6. (Tables 17, 18, 19, 20). The 
per cent of conversion at the maximum point is greater than with 
the use of 0.25 cc or 0.5 cc of 0.01 M PAP as used in Tables I 
and II. 
Table I (4) showed a maximum at 23 hours of 73.7%; Table 
II (12) showed maximum production of 93.0% at 16 hours. In Table 
III (20) the 8 hour maximum was a 96% conversion. 
Table IV - With the use of 0.5 cc of 0.01 M PAP the time interval 
is only slightly shortened. From the 4 and 8 hour readings obtained 
it would appear that the maximum production produced by this amount 
of PAP occurs in about 7-9 hours. Comparison here between initial 
rate, per cent of production and THb continues to give no correla-
tion between the total pigment and the initial rate or per cent 
of production. 
Table V - This Table presents tests using 0.5 cc PAP identical with 
some of those previously run but with glucose, in increments of 
100 mgm.%, added. This does not account, however, for the normal 
glucose content of the blood which is unknown o 
Table 25 - 100 mgm. of glucose ·added to test described in Table 9 re-
sults in an increased initial speed and a relative similarity 
thereafter. 
Table 26 - 100 mgm. glucose shows a decrease in initial speed and a 
slight decrease in MHb production. 
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Table 27 - 200 mgm. glucose shows an increase in initial speed of 
production and an increase in total MHb production. 
Table 28 - 200 mgm. glucose. Slight increase in initial production 
but a large decrease in total MHb production. 
Table 29 - 150 mgm. glucose. No change in initial rate but an in-
crease in the total production. 
Table 30 - 300 mgm. glucose - same as Table 29. 
Table 31 - 450 mgm. glucose. Increase in initial rate; no change 
in the total MHb production. 
Table 32 - 400 mgm. glucose. Initial rate is doubled and the 
total production is halfed. 
Table 33 - 400 mgm. glucose. Initial speed is greatly increased 
but the total production is decreased to less than one-half. 
Addition of small amounts of glucose (100-400 mgm.) to MHb producing 
solutions in vitro provide a variety of results with both initial speed 
and the total production. OnlY when the addition of glucose has reached 
proportions accounted for by the addition of 400 mgm. or more of glucose 
plus the original unknown content of the blood does any definite result 
occur. This addition of glucose greatlY increases the initial rate of 
production but seeminglY inhibits the total production. The effect of 
still greater amounts of glucose remains for further experimentation. 
All Tables showing a decrease in the per cent of MHb after the peak 
has been reached must not be attributed to the enzynatic action of the 
blood. Since the methods of determination require the laking of the 
blood, it is probable that when the maximum production of MHb is reached 
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there is a breakdown of the oxidation products of PAP and the MHb-Hb 
equilibrium s,ystem. Therefore, those values only demonstrate that the 
peak of MHb production has been passed rather than any reversal of that 
production. 
D. Conclusions 
1. Increasing doses of PAP have no definite effect upon the initial 
rate of MHb production in vitro. 
2. Increasing doses of PAP serve to decrease the time required for 
maximum production in individual samples and convert a larger 
percentage of Hb -+ MHb. As the dose increases, the shortening 
of the time interval becomes less and the increase in the per-
centage conversion becomes smaller. It appears that there is a 
maximum level at which there would be no further increase in 
total production and the conversion would occur in minimum of 
time. 
3. There seems to be no correlation between initial rate and total 
production of MHb and the THb of the sample. 
4. Addition of glucose up to 400 mgm. per cent seems to have no 
definite effect upon either the initial rate or the total pro-
duction of MHb. 
50 Glucose· content well above 400 mgm. per cent causes a change in 
the s,ystem resulting in a higher initial speed of production 
and an inhibitory effect upon the total production of MHb. 
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